Malignant Carcinoid Syndrome
A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
Subtype terms (1)
More specific conditions that are subtypes of Malignant Carcinoid Syndrome in the MeSH hierarchy.
- Carcinoid Heart Disease
3 drugs approved
Drugs by status
Approved for this indication (2)
Phase 4 trials (1)
Phase 3 trials (2)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (23)
- Amgen
- Endo Pharmaceuticals
- Boston University
- Cancer Biotherapy Research Group
- University of London
- Cornell University
- Eastern Cooperative Oncology Group
- Federation Francophone de Cancerologie Digestive
- Northwestern University
- Ohio State University
- University of South Florida
- University of Southern California
- University of Toronto
- Wayne State University
- Mayo Clinic
- Mid-Atlantic Oncology Program
- University of Cambridge
- University of Texas at Houston
- University of Wisconsin
- University of Paris
- George Washington University
- Cancer Therapeutics, Incorporated
- Yeshiva University
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (3)